<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04476797</url>
  </required_header>
  <id_info>
    <org_study_id>GTI-4711-101</org_study_id>
    <nct_id>NCT04476797</nct_id>
  </id_info>
  <brief_title>Phase 1/2 Study of SBRT With or Without GC4711 for NSCLC</brief_title>
  <official_title>Phase 1/2 Study of Stereotactic Body Radiation Therapy (SBRT) With or Without GC4711 for Early Stage, Centrally Located or Large Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galera Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galera Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GTI-4711-101 is a Phase 1-2 study of the safety of GC4711, and its potential to reduce&#xD;
      radiation-related pulmonary injury due to SBRT for early stage large or central localized&#xD;
      NSCLC. After an open-label, Phase 1, safety cohort of approximately 5 subjects has been&#xD;
      completed, a randomized, double-blind, placebo-controlled Phase 2 portion will be conducted.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects must be referred for SBRT with large (&gt;3cm) or central localized, node negative,&#xD;
      non-metastatic NSCLC, and have an ECOG PS score of 0-3 to be considered for enrollment.&#xD;
      Subjects with small peripheral lesions(≤3cm) are excluded, as the aim is to improve outcome&#xD;
      in larger, central NSCLC carrying a higher risk of pneumonitis, as well as poorer local&#xD;
      control. Feasibility of SBRT is judged by the treating physician. Chemotherapy given before&#xD;
      SBRT is permitted, but subjects must be immunotherapy naive.&#xD;
&#xD;
      SBRT is planned on the (persistent) PET+ tumor location for a dose of 10-12 Gy in 5&#xD;
      fractions, delivered on sequential weekdays. In the Phase 1, 5 subjects will each receive&#xD;
      GC4711 by 15-minute IV infusion, before each SBRT fraction After the Phase 1, a Phase 2,&#xD;
      randomized, double-blind, placebo-controlled study phase will be initiated, wherein&#xD;
      approximately 66 subjects referred for SBRT with early stage large or central localized NSCLC&#xD;
      will be randomized in a 1:1 ratio to receive either GC4711 or placebo given intravenously&#xD;
      (IV) before each fraction of SBRT.&#xD;
&#xD;
      All subjects will be evaluated for changes in the diffusion capacity of carbon monoxide&#xD;
      (DLCO) and pneumonitis. All subjects will be followed for 12 months for treatment related&#xD;
      adverse effects, disease control (Progression Free Survival (PFS), Overall Survival (OS),&#xD;
      Distant Metastases (DM) rate and local control-(RECSIST 1.1), and quality of life (FACT-L) A&#xD;
      Data Monitoring Committee will be established for the Phase 2 portion of the study to provide&#xD;
      independent monitoring of safety given the blinded design.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of dose-limiting toxicities during treatment and within 30 days post SBRT</measure>
    <time_frame>DLT 30 days post SBRT</time_frame>
    <description>Phase 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DLCO measured by RTOG scale 3 months after completion of SBRT compared to baseline</measure>
    <time_frame>DLCO 90 days post SBRT</time_frame>
    <description>Phase 2</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">71</enrollment>
  <condition>SBRT</condition>
  <condition>NSCLC</condition>
  <condition>Non-metastatic</condition>
  <arm_group>
    <arm_group_label>Arm A Active GC4711</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC4711</intervention_name>
    <description>15 minute IV Infusion</description>
    <arm_group_label>Arm A Active GC4711</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>15 minute IV infusion</description>
    <arm_group_label>Arm B Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects at least 18 years of age.&#xD;
&#xD;
          2. Ability to understand and the willingness to sign a written informed consent.&#xD;
&#xD;
          3. Histological or biopsy proven NSCLC. For peripheral lesions, cytology and/or clear&#xD;
             imaging-guided suspicion is accepted if histology cannot be obtained.&#xD;
&#xD;
          4. ECOG performance status of 0-3.&#xD;
&#xD;
          5. Large (&gt;3cm) or centrally localized (within 2cm in all directions around the proximal&#xD;
             bronchial tree, including ultra-central tumors, abutting the bronchial tree or&#xD;
             trachea), node negative and non-metastatic NSCLC, judged acceptable for SBRT by the&#xD;
             treating Investigator. Staged with FDG-PET/CT, brain CT or MRI with contrast and/or&#xD;
             mediastinoscopy, measurable disease as defined by RECIST 1.1.&#xD;
&#xD;
          6. Adequate end-organ function, based on routine clinical and laboratory workup:&#xD;
&#xD;
               1. ANC &gt;1,000 cells/µl, Platelets ≥ 75,000 cells/µl, Hemoglobin ≥ 8.0 g/dl&#xD;
&#xD;
               2. Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 50 ml/min&#xD;
&#xD;
               3. Total bilirubin ≤ 1.5 x ULN (or direct bilirubin below the ULN), AST and ALT ≤&#xD;
                  2.5 x ULN&#xD;
&#xD;
               4. International normalized ratio (INR) (or prothrombin time (PT)) and activated&#xD;
                  partial thromboplastin time (aPTT) ≤ 1.5 x ULN unless participant is receiving&#xD;
                  anticoagulant therapy, if values are within the intended therapeutic range&#xD;
&#xD;
          7. Males and females of must agree to use effective contraception starting prior to the&#xD;
             first day of treatment and continuing after the last dose of GC4711/Placebo for 30&#xD;
             days (females) and 90 days (males).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with confirmed nodal and/or distant disease(including brain), according&#xD;
             standard workup by local investigator&#xD;
&#xD;
          2. Subjects with peripheral lesions 3cm or smaller&#xD;
&#xD;
          3. Prior treatment with immunotherapy&#xD;
&#xD;
          4. Prior intra-thoracic radiotherapy or surgery with substantial overlap in former&#xD;
             radiation fields as determined by the treating radiation oncologist.&#xD;
&#xD;
          5. Subjects not recovered/controlled from prior treatment-related (chemotherapy or&#xD;
             targeted therapy) toxicities judged by treating physician.&#xD;
&#xD;
          6. Uncontrolled malignancy other than lung cancer that requires active treatment or is&#xD;
             deemed by the treating physicians to be likely to affect the subject's survival&#xD;
             duration.&#xD;
&#xD;
          7. Subjects unable to lie down with arms up with a regular breathing pattern.&#xD;
&#xD;
          8. History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to GC4711.&#xD;
&#xD;
          9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that, in the opinion of the&#xD;
             investigator, would limit compliance with study requirements.&#xD;
&#xD;
         10. Participation in other clinical trials either to treat diagnosed lung cancer or to&#xD;
             reduce the toxicity of therapy from participating in GC4711 clinical trial.&#xD;
&#xD;
         11. Requirement for concurrent treatment with nitrates or other drugs that may, in the&#xD;
             judgment of the treating investigator, create a risk for a precipitous decrease in&#xD;
             blood pressure.&#xD;
&#xD;
         12. Female subjects who are pregnant or breastfeeding.&#xD;
&#xD;
         13. Any other conditions that, in the Investigator's opinion, might indicate the subject&#xD;
             to be unsuitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Holmlund, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kara Terry</last_name>
    <phone>610-725-1500</phone>
    <email>kterry@galeratx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jon Holmlund, MD</last_name>
    <phone>610-725-1500</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Li</last_name>
      <phone>480-878-2022</phone>
    </contact>
    <investigator>
      <last_name>Ying Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center at NCMC</name>
      <address>
        <city>Greeley</city>
        <state>Colorado</state>
        <zip>80631</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Gasper, MD</last_name>
      <phone>970-810-6690</phone>
    </contact>
    <investigator>
      <last_name>Laurie Gasper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IACT Health</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas Ciuba, MD</last_name>
      <phone>706-596-5413</phone>
    </contact>
    <investigator>
      <last_name>Douglas Ciuba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Vollstedt</last_name>
      <phone>319-353-7143</phone>
    </contact>
    <investigator>
      <last_name>Bryan Allen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Akhavan</last_name>
      <phone>913-588-6046</phone>
    </contact>
    <investigator>
      <last_name>David Akhavan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parag Parikh, MD</last_name>
      <phone>313-916-2600</phone>
    </contact>
    <investigator>
      <last_name>Parag Parikh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tykeytra Dale</last_name>
      <phone>919-668-3726</phone>
    </contact>
    <contact_backup>
      <last_name>Linda Kaltenback</last_name>
      <phone>919-681-6804</phone>
    </contact_backup>
    <investigator>
      <last_name>Christopher Kelsey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tithi Biswas, MD</last_name>
      <phone>216-844-5336</phone>
    </contact>
    <investigator>
      <last_name>Tithi Biswas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gibbs Cancer Center &amp; Research Institute</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Curtis, MD</last_name>
      <phone>864-560-6954</phone>
    </contact>
    <investigator>
      <last_name>Amy Curtis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Curtin</last_name>
      <phone>214-645-3622</phone>
    </contact>
    <investigator>
      <last_name>Puneeth Iyengar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Regional Medical Center</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Wisbeck, MD</last_name>
      <phone>425-297-5500</phone>
    </contact>
    <investigator>
      <last_name>William Wisbeck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Fairbanks, MD</last_name>
      <phone>509-228-1000</phone>
    </contact>
    <investigator>
      <last_name>Robert Fairbanks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 15, 2020</study_first_submitted>
  <study_first_submitted_qc>July 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2020</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Early stage large or central NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

